Linked Life Data

19200455

Source:http://linkedlifedata.com/resource/pubmed/id/19200455

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7-8
pubmed:dateCreated
2009-3-30
pubmed:abstractText
With the advent of targeted therapies promising to revolutionise the nature and success of patient care, the field of clinical oncology is facing a highly exciting future. While much of this enthusiasm comes from the hope for improved patient outcomes, a review of clinical response/relapse rates for current therapies provides a more sobering perspective. Given that the majority of patients are intrinsically resistant to the therapeutic potential of these molecules, efforts are now directed at characterising such non-responsive system behaviour and causative molecular insults. Testament to this is an expanding catalogue of target and system-based aberrations, often defined through retrospective analyses of clinical tissue and associated outcome data. What has emerged is a complex picture, where numerous potential sources of cancer-specific aberration can contribute to refractory tumour behaviour. Clinicians, regulators and sponsors must now collaborate to determine how such knowledge should be used to enhance the clinical decision process and associated regulatory guidance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1878-5832
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
373-9
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Molecular perspectives on the non-responder phenomenon.
pubmed:affiliation
LIFE Biosystems GmbH, Poststrasse 34, Heidelberg 69115, Germany. jackson@lifebiosystems.com
pubmed:publicationType
Journal Article, Review